Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.76 |
| ▸ | MAPT | P10636 | 15/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 6/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10680090 | 0.82 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL6710998 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL27845811 | 0.76 | MAPT (0.69) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL1127218 | 0.75 | ALDH1A1 (0.66) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL5741339 | 0.73 | SIRT6 (0.62) | ALDH1A1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL6151230 | 0.73 | SIRT6 (0.81) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL15271381 | 0.73 | SIRT6 (0.81) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL28398268 | 0.73 | MAPT (1.00) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL2074819 | 0.73 | MAPT (0.68) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL29057437 | 0.73 | MAPT (0.68) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | PIERRE FABRE MEDICAMENT (FR) | 2004-05-13 | — | — | US | disclosed |
| EP-1324999-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030927-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | CBR3, CBR1, HCCS | ALDH1A1 3031/4885MAPT 4753/4885SMN1; SMN2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.